

## Susan D. Tiedy-Stevenson

Senior Director  
Washington, D.C.

### Biography

Susan Tiedy-Stevenson assists clients in obtaining FDA marketing approvals and clearances for diagnostic tests and medical devices. She works with clients throughout the life cycle of product development in assessing FDA quality system requirements, clinical and analytical development, and implementation of post-marketing strategies. Susan is attuned to the needs of large corporations and start-up companies in formulating practical solutions to address FDA regulatory requirements.

She has deep insight into the FDA's biologics and medical device regulation of in vitro diagnostics (IVD) assays and related instruments, accessories, laboratory developed tests, and drug companion diagnostics. Susan also assists clients concerning FDA regulation of non-IVD medical devices including, in part, diabetes diagnostic and treatment devices and standalone software diagnostic applications.

Previously, Susan held executive management positions in regulatory, clinical, and quality for IVD, medical device, and biologic product companies and was responsible for preclinical and clinical study programs, development of regulatory strategies and premarketing submissions to the FDA and international authorities, and establishment and monitoring of good manufacturing practice programs compliant with FDA



### Phone

+1 202 637 5459

### Fax

+1 202 637 5910

### Email

[susan.tiedy-stevenson@hoganlovells.com](mailto:susan.tiedy-stevenson@hoganlovells.com)

---

### Practices

Medical Device and Technology  
Regulatory

---

### Industries

Life Sciences and Health Care

---

regulations.

## Representative experience

Obtained the first HPV test for cervical cancer and continued to secure additional FDA approvals for HPV assays \*

Secured the FDA's first ever Clinical Laboratory Improvement Amendments (CLIA) waiver approval for doctor office syphilis testing.

Obtained PMA approval and 510(k) clearances for a variety of medical devices.

Trained companies and entrepreneurs on FDA premarketing and CLIA waiver submission requirements.

\*Matter handled prior to joining Hogan Lovells.

## Latest thinking and events

- News
  - FDA Pre-Cert update: “more work needed” to refine Streamlined Review Framework
- News
  - HHS ends EUA requirement for Laboratory Developed Tests; FDA may continue to assert authority
- News
  - FDA updates FAQ on COVID-19 tests and validation
- Press Releases
  - Hogan Lovells’ Medical Device & Technology practice reflects on its COVID-19 work and looks ahead to what may come next
- Webinar
  - COVID-19 Webinar: Considerations for the Food and Agriculture Sector When Testing Employees for Coronavirus
- Press Releases

## Areas of focus

Advertising and Promotion  
Compliance

In Vitro Diagnostics

Medical Devices

Combination Products, FDA  
Jurisdictional Issues, FDA  
Postmarket Compliance Issues

---

## Education and admissions

### Education

M.S., Central Michigan University,  
1979

Graduate Studies, University of  
Pittsburgh, 1974

B.S., Chatham College, 1972

---

## Memberships

AMDM Companion Diagnostics  
Working Group

Regulatory Affairs Professional  
Society

---

- Hogan Lovells and Wanda Henry Co. advise Sansure Biotech, Inc. in obtaining FDA Emergency Use Authorization for COVID-19 molecular test kit